Discover
IKT
Inhibikase Therapeutics, Inc.
1.94
2 x 1.52
2 x 2.45
bid
ask
-
0.09
4.43%
2 @ 04:04 AM
1.94 +0.00 (0.00%)
| Ytd | -5.37% | |
| 1y | -0.51% |
1.91
day range
2.10
1.33
52 week range
2.26
| Open | 2.02 | Prev Close | 2.03 | Low | 1.91 | High | 2.10 | Mkt Cap | 256.14M |
| Vol | 913.99K | Avg Vol | 848.78K | EPS | -0.44 | P/E | N/A | Forward P/E | -11.84 |
| Beta | 1.12 | Short Ratio | 0.17 | Inst. Own | 11.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 1.80 | 200-d Avg | 1.71 | 1yr Est | 7.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.38 | -0.65 | -0.27 | -71.05% |
| 2024-08-14 | 2024-06 | -0.58 | -0.66 | -0.08 | -13.79% |
| 2024-08-14 | 2024-06 | -0.58 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | -0.79 | -0.73 | 0.06 | 7.59% |
| 2024-05-15 | 2024-03 | -0.79 | N/A | N/A | N/A |
| 2024-03-27 | 2023-12 | -0.78 | -0.63 | 0.15 | 19.23% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-08 | Jefferies | Upgrade | Buy | |
| 2024-10-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-20 | BELLINI ROBERTO | Director | 0.00 | Purchase |
| 2024-10-20 | KUSH ARVIND | Director | 145.00K | Purchase |
| 2024-10-20 | MUNSHI AMIT D | Director | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 626.50K | 1.85M | 0.93% |
| 2024-09-29 | Blair (William) & Company, L.L.C. | 126.12K | 373.32K | 0.19% |
| 2024-09-29 | Geode Capital Management, LLC | 50.07K | 148.19K | 0.07% |
| 2024-09-29 | Renaissance Technologies, LLC | 19.92K | 58.97K | 0.03% |
| 2024-09-29 | Vanguard Group Inc | 16.72K | 49.50K | 0.02% |
| 2024-09-29 | State Street Corporation | 10.08K | 29.85K | 0.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 36.38K | 107.69K | 0.05% |
| 2024-09-29 | 360 Funds-Timber Point Global Tactical Allocation Fd | 11.00K | 32.56K | 0.02% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 16.72K | 49.50K | 0.02% |
| 2024-10-30 | Fidelity Total Market Index Fund | 11.48K | 33.99K | 0.02% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 8.58K | 25.39K | 0.01% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 3.27K | 9.69K | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 6 | 2023-06-30 |